Crucell suspends delivery of flu vaccines to Italy

Crucell, the vaccines arm of Johnson & Johnson ($JNJ), suspended a delivery of 2.36 million seasonal flu vaccine doses to Italy, Reuters reports. The company stopped the planned supply of its Inflexal V vaccine after two of 32 lots failed quality checks. Report

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.